| Name | Title | Contact Details |
|---|---|---|
Teri Takai |
Chief Information Officer | Profile |
Bio-Tissue®, a subsidiary of TissueTech™, is the leader in regenerative biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye. Eye care professionals understand that good medicine is based on good science. Bio-Tissue® prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue® adheres to the FDA tissue and medical device guidelines.
Proper is the modern approach to better sleep - evidence-based, personalized, and holistic, offering premium PhD-designed natural sleep supplements & expert sleep coaching.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.
Orthopaedic Associates of Michigan is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.